Regulatory Education for Industry: 2019 Complex Generic Drug Product Development Workshop – Sep. 25-26, 2019 - 09/25/2019 - 09/26/2019
- September 25-26, 2019
- September 25, 2019
Event LocationThe Hotel
at the University of Maryland
7777 Baltimore Ave.
College Park, MD 20740
Digital LocationAttend in-person or online
Norman E. "Ned" Sharpless,
Leadership RoleActing Commissioner of Food and Drugs - Food and Drug Administration
- Organized By:
You may attend in-person or virtually. This event is FREE.
Acting Commissioner of Food and Drugs
Norman E. “Ned” Sharpless, M.D.
As a continuation from the 2018 workshop on complex generic drug products, the goal of this science-focused workshop is to communicate to the generic industry how FDA research outcomes guide and facilitate complex generic drug product development. FDA will link GDUFA science and research on complex drug products to product-specific guidance development, discuss pre-ANDA meetings and review, and examine various areas of complex product science.
Complex drug products often have features that make them harder to develop as generics under traditional approaches. These challenges can mean these ANDAs may undergo more assessment cycles than other ANDAs for non-complex generic drug products before receiving FDA approval, which, in turn, may result in limited competition. That is why the FDA has made facilitating the development and approval of complex generic drug products a major focus of the FDA’s Drug Competition Action Plan, which is aimed at encouraging generic drug competition in an effort to help reduce drug prices. It is our hope that the Complex Generic Drug Product Development Workshop will help facilitate the development and approval of ANDAs for complex generic drug products and the introduction of more generic medicines to the complex drug marketplace.
- Pre-ANDA program update
- FDA’s inactive ingredient database: improvements on the path to 2020
- Scientific and regulatory advances for generic topical and transdermal drug product development
- Characterization of complex injectable active pharmaceutical ingredient API and formulations
- Bioequivalence approaches for complex injectable API and formulations
- Complex drug-device combination products – injectable drug products
- Complex drug-device combination products – orally-inhaled and nasal drug products
- Quantitative methods and modeling-informed regulatory decision making
Scientists, researchers, and regulatory affairs professionals who work on or are interested in working on the development of complex generic drugs.
After this workshop, participants will be able to:
- Explain various mechanisms and processes that industry can use to obtain advice from the FDA to facilitate complex generic drug product development; and
- Summarize new developments in science, guidance, and review experience for specific types of complex generic drug products.
Continuing Education Credits
- has been pre-approved by RAPS as eligible for up to 12 credits towards a participant’s RAC recertification upon full completion.
- is eligible for SOCRA credit in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area. Candidate must provide documentation of participation.
- has been pre-approved by SQA as eligible for 0.25 non-GCP or non-GLP units for every 1 hour of instructional time towards a participant’s RQAP re-registration.
- has been approved by ACRP for medical education credits. Contact hours are provided at 1 unit for at least 45 minutes of qualified material.
This event will not offer CME, CPE, or CNE.
- Generic Drug Science and Research
- Guidance for Industry, Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA
- Draft Guidance for Industry, Controlled Correspondence Related to Generic Drug Development
- Draft Guidance for Industry, Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA
- Product-Specific Guidances for Generic Drug Development
- Upcoming Product-Specific Guidances for Complex Generic Drug Product Development
- Draft Guidance for Industry, Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - Quality Considerations
- Guidance for Industry, Safety Considerations for Product Design to Minimize Medication Errors
Onsite Attendance Information
Learn more about the venue’s room block, transportation, and parking information.
This meeting will be recorded.
The audio for the event will be provided through your computer speakers via Adobe Connect (there will NOT be a teleconference number to dial into). We recommend that you test your PC or mobile device prior to the event and you join the event a few minutes early to address any issues.
To test your PC, please visit:
Adobe Connect Diagnostic Test
Please contact firstname.lastname@example.org for all technical questions.
For Reasonable Accommodations
If special accommodations at the workshop are needed due to a disability, please email CDERSBIA@fda.hhs.gov at least 7 days in advance of the workshop date. Requests for sign language interpretation or Computer Aided Realtime Translation (CART)/captioning should be made 2 weeks in advance of the workshop and should be sent directly to the FDA Interpreting Services Staff email account: email@example.com.
- CDER Small Business and Industry Assistance
- Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
- (866) 405-5367